AI / data analytics / healthtech / informatics

#AI #AI / data analytics / healthtech / informatics #Data #Healthcare #Life sciences #Machine learning

Making life science data work for the digital age

The life sciences data landscape is growing in complexity and scale, with organisations generating increasingly high volumes of data. Yet, these data are still stored and searched using outdated methods. As a result, there are vast amounts of unstructured data stored in various siloed locations. Vladimir Makarov, Consultant at Pistoia… Read More

#Exclusive Content #News #Opinion

#AI / data analytics / healthtech / informatics #Biosciences #Drug development #Therapeutics

Analytical challenges when characterising complex molecules

Michael-John O’Connor, Director of Biochemical Services at BioPharmaSpec, discusses analysing biosimilars, glycosylated mAbs and PEGylated proteins with Lu Rahman.  LR: Outline the importance of bio-molecules in drug discovery. What is their potential within therapeutic development?    MJOC: The FDA’s recent approval of Biocon’s Semglee (long acting Insulin glargine) is the first example of an interchangeable biosimilar that can be substituted… Read More

#Exclusive Content #News

#AI #AI / data analytics / healthtech / informatics #Drug design #Drug development #Drug discovery

AI round-up: the expanding influence of AI in drug discovery 

Artificial intelligence (AI) is intelligence demonstrated by machines, as opposed to intelligence demonstrated by animals (including humans). According to a report by IDTechEx, the application of artificial intelligence (AI) in the drug discovery process is promising to drastically cut down timelines and costs of bringing new therapies to patients. They say the potential for… Read More

#Editor's Choice #Exclusive Content #News

#AI / data analytics / healthtech / informatics #Assay #Drug discovery #Electronic Lab Notebooks (ELN) #Research #Screening

Digitalisation of VIB’s biomedical research with CDD Vault 

This paid-for advertorial by CDD Vault appeared in the DDW / ELRIG UK Drug Discovery 2021 supplement in DDW Volume 22, Issue 4 – Fall 2021   For any research-based organisation in the life sciences arena, experimental data is the key to deriving biological and biochemical insight and understanding, and ultimately driving… Read More

#Exclusive Content

#AI / data analytics / healthtech / informatics #Biorepository #Cell / tissue culture #Machine learning

BioIVT enhances its website to facilitate drug and diagnostic R&D

BioIVT has added advanced tissue, biofluid and cell search and e-commerce capabilities to its website, which is enabling customers to mine its biospecimen repository and related clinical database using artificial intelligence (AI) and machine learning (ML) applications to advance scientific knowledge of different diseases.   According to BioIVT, more than… Read More

#News

#AI / data analytics / healthtech / informatics #Drug discovery #Technology

Oncology is a major focus for AI drug discovery companies

The application of artificial intelligence (AI) in the drug discovery process is promising to drastically cut down timelines and costs of bringing new therapies to patients. The potential for AI to address these pain points has drawn significant attention from investors and players in the pharmaceutical industry.  Typically, the development… Read More

#Market Reports #News #Trends & Analysis

#AI #AI / data analytics / healthtech / informatics #Drug targets

AI-driven platform identifies novel ulcerative colitis target

BenevolentAI has idenitifed a preclinical candidate for a novel ulcerative colitis target. It is in IND/CTA-enabling studies and the company plans to advance it to move the programme into the clinic in early 2023. Scientists deployed BenevolentAI’s target ID tools and machine learning models to identify and experimentally validate a novel biological… Read More

#News

#AI / data analytics / healthtech / informatics #Software #Technology

CDD launch free software tool 

Collaborative Drug Discovery (CDD) has released a free, full featured, standalone software tool: CDD Visualization. It is a browser-based application that allows scientists to visualise data and generate publication-ready graphs and plots.  If researchers are willing to share their data with the community, CDD hosts it for free. CDD… Read More

#News

#AI / data analytics / healthtech / informatics #Biopharmaceutical #Drug discovery #Machine learning

The value of scientific intelligence in drug discovery

Leif Pedersen, President, Software, and David Lowis, Executive Director of Scientific Informatics at Certara, explain how scientific intelligence can refine and increase the effectiveness of critical decision points in drug discovery. Strong scientific intelligence capabilities are essential building blocks for a scientific informatics strategy and will increase the effectiveness of… Read More

#Exclusive Content #News

#AI #AI / data analytics / healthtech / informatics #Healthcare #Precision medicine

AI in drug discovery: from Alzheimer’s to precision medicine 

Artificial Intelligence (AI) is the simulation of human intelligence processes by machines, particularly computer systems, and finds itself at a climactic moment for its use within the drug discovery industry, especially as the world emerges from the Covid-19 pandemic.   “Artificial intelligence and machine learning continue to play… Read More

#hidden

#AI #AI / data analytics / healthtech / informatics #Clinical trials #Technology

DDW AI expert exclusive: Boosting innovation in medicine 

In 18 months, vaccine research advanced AI in medicine by five to seven years. That’s cause for optimism — and investment — in the digital transformation of clinical development says Jeff Elton, CEO of Concerto HealthAI, who has extensive experience in this sector, and shares his insight with DDW.  In… Read More

#News

#AI #AI / data analytics / healthtech / informatics #Drug development #Drug discovery #Pharma #Technology

Exclusive interview: BenevolentAI on the future of AI

In what BenevolentAI considers a move that deepens its drug discovery and development expertise on its board, Dr John Orloff has been appointed as a Non-Executive Director. Dr Orloff joins the BenevolentAI board as it advances plans to scale its AI platform, partnerships and drug portfolio. DDW’s Megan Thomas speaks with Dr Orloff about his… Read More

#Editor's Choice #Exclusive Content #News #Opinion #Trends & Analysis

#AI #AI / data analytics / healthtech / informatics #Collaboration #Drug discovery #Molecular Biology

IBM Research and Arctoris accelerate closed loop drug discovery 

IBM Research and Arctoris are investigating the application of AI and automation to accelerate closed loop molecule discovery.   IBM Research has developed RXN for Chemistry, an online platform leveraging Natural Language Processing (NLP) architectures to automate synthetic chemistry. Representing chemical reactions via SMILES (Simplified Molecular Input Line Entry System),… Read More

#News #Trending News

#AI / data analytics / healthtech / informatics #Assays #Covid-19 #Drug development

Human studies begin on AI Covid-19 treatment with up to 97% effectiveness

Skymount Medical and Louisiana State University (LSU) have commenced human studies on a unique combination of therapies for Covid-19 patients, known as SM-19. In vitro and in vivo assays conducted by the IIT Research Institute (IITRI) in Chicago showed significant efficacy in reducing viral load of the SARS-Cov-2 virus. The… Read More

#News #Trending News

#AI / data analytics / healthtech / informatics #Cancer research #Drug discovery #Exscientia #Immuno-oncology

Spotlight: AI in drug discovery first

Earlier this year, Exscientia announced what was said to be the first AI-designed immuno-oncology drug to enter clinical trials. Lu Rahman talks to CEO Andrew Hopkins about the company’s work and use of AI in drug discovery. LR:  How AI has been used in this process and what benefits has… Read More

#Cancer Research #Editor's Choice #Exclusive Content #News

#AI #AI / data analytics / healthtech / informatics #Clinical trials #Drug discovery

Insilico Medicine discovers preclinical candidate for kidney fibrosis using AI

Insilico Medicine has announced today that its AI-powered drug discovery platform has delivered a preclinical candidate for kidney fibrosis. The preclinical candidate has desirable pharmacological properties and pharmacokinetic profile and has demonstrated highly promising results in in-vitro and in-vivo preclinical studies. Insilico Medicine is working to advance this program to… Read More

#News